Background: Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis
It is important to examine the extent to which patients with established access received discontinuous HCV care and its impact on receipt of DAA treatment. Identifying underlying sources of variation as well as subgroups at high risk of being lost to follow-up can guide the clinicians and healthcare systems in spreading the benefits of the new agents to more patients, leveraging their impact on cirrhosis and related complication reductions. Therefore, we sought to estimate and identify the proportion of patients with established access to HCV clinics who had a follow-up visit and received DAA treatment within the first 16 months of DAA availability. We also determined the reasons underlying lack of clinic follow and anti-viral treatment.
We use data from the US Veterans Administration (VA) healthcare system for this study. The VA is the largest integrated healthcare system in the US and has a disproportionate number of patients with HCV. The VA system is federally funded and equal access system that provides free or subsidised healthcare to the US veterans. It is also a semi-closed system with a relatively stable patient population, making long-term studies possible. 10 , 11 
| MATERIALS AND METHODS
We used mixed methods for our study. Specifically, using an administrative and clinical database, we determined the proportion of patients, who had HCV clinic follow-up and who received treatment in an observational national level cohort of patients previously seen in HCV clinics. We then conducted a structured review of patient medical charts to explain findings from the database analysis.
| Database analyses

| Data source
We used the VA national Corporate Data Warehouse (CDW) for this study. CDW data exist on the VA Informatics and Computing Infrastructure (VINCI) platform in a relational database. It includes all laboratory test results as well as inpatient and outpatient utilisation as indicated by procedure (CPT/ICD-9 procedure codes) and diagnosis (ICD-9 codes) codes for each encounter and admission. The database also includes separate files for patient demographics and pharmacy utilisation.
| Study cohort
We identified a retrospective cohort of patients with positive HCV RNA test recorded from 1999 to 2013, and included those 18 years of age or older who had at least one visit in the VA HCV specialty clinics between May 1, 2009 and December 1, 2013 (date of approval of the first 2nd generation DAA, sofosbuvir). We selected this timeframe for cohort accrual to match the timeframe for an existing study used for our medical chart review component, below.
| Study outcomes
Our primary outcomes were follow-up in specialty clinic and receipt of DAA treatment from December 1, 2013 to April 30, 2015. In the VA, anti-viral treatment is rendered by gastroenterologists (clinic stop code 307), infectious disease (310) and (in some VA facilities) by primary care providers (323). To ascertain which of these three clinics served as a specialty clinic for each VA facility, we used pharmacy data and determined the clinic responsible for writing the majority of the DAA prescriptions for HCV patients in a given facility, as described previously. We classified a patient as having seen the specialists if he or she had a clinic visit to the specialty clinic, which was accompanied with diagnostic codes for HCV, cirrhosis or chronic liver disease not specified. In our previous work, we found a high agreement between this definition and chart documented specialty evaluation as the gold standard (agreement index~75%). 7 We defined DAA treatment >1 filled prescription of sofosbuvir, ledipasvir, simeprevir or ombitasvir-paritaprevir-ritonavir with or without ribavirin.
| Predictors
We examined several factors derived from CDW. 
| Statistical analysis
We created two multivariable logistic generalised estimating equation (GEE) models to estimate the probability of being seen in the HCV specialty clinics during the study follow-up and, among those who were seen, the probability of receiving DAAs. linear association between the number of visits with the PCP and odds of having a follow-up in HCV clinic (see Table S1 ).
The factors associated with receipt of DAAs were similar to Table S2 ).
| Medical record review
We conducted a review of medical records of 905 patients who were seen in the HCV specialty clinics in MEDVAMC in Houston, TX in the pre-DAA era (Figure 1 ). Of these patients, 509 (56.2%) patients had a follow-up visit in the HCV specialty clinic during the study time frame.
Among the 396 patients without HCV clinic follow-up, 148 (37.4%) patients relocated to another geographic locale and were no longer receiving care at the MEDVAMC. Of these only 30 patients (20.3% of 148, 7.6% of total without follow-up at MEDVAMC) were seen in the HCV clinics at their new VA facility and 10 (6.8% of 148, 2.5% of total without follow-up at MEDVAMC) received DAA ( Figure 2 ).
Of 248 patients who had ongoing care at MEDVAMC yet did not have HCV clinic follow-up, 63 (25.4%) had scheduled appointments in HCV clinics that they missed or cancelled (Figure 2 ).
Among these patients (who missed or cancelled the follow-up appointments), only 17 (27.0%) had a documented reason in the chart for not following up in the HCV clinic (n = 6, 9.5% physical or mental health co-morbidity; n = 4, 6.3% patient preference).
T A B L E 1 (Continued)
Re-seen during study duration N = 47 165
Not re-seen during study duration N = 37 056 and treatment, including ongoing alcohol abuse (n = 27, 14.6%), illicit drug use (n = 20, 10.8%) and medical or psychiatric co-morbidity (n = 8, 4.3% and n = 9, 4.9%, respectively). Approximately, 10.8%
(n = 20) of patients preferred not to seek HCV care. Although these patients were enrolled in primary care, the need for HCV clinic follow-up was not addressed by PCP for 56.2% (n = 104) of the patients.
Of the 509 patients with specialty clinic follow-up, 255 (50.1%)
were not treated as of April 30, 2015. The most common reasons for lack of treatment receipt included decision to wait for newer DAA therapy (n = 99, 38.8%), followed by medical co-morbidities (n = 66, 25.9%), and ongoing alcohol or illicit drug use (n = 63, 24.7%) ( 
| DISCUSSION
Our study has three key findings.
We found that in a system with equal and easy access to the new DAAs, fewer than 50% of HCV-infected veterans with previously established care in HCV clinics were re-seen within 16 months of the approval of DAA, and only 27% of these patients ary criteria were based on concerns that patients will be unable to comply with long and toxic treatments as well as the risk of re-infection with ongoing drug use. However, data show that patients with a prior history of drug abuse have similar sustained response to treatment as patients without history of drug use. 15 In a systemic review and meta-analysis, patients with active drug use undergoing interferon-based therapy had a pooled SVR of 55.5%, which was similar to the general population. 16 Patients with drug use and those with alcohol abuse represent two important subpopulations: patients with co-morbid alcohol abuse are at a high risk of cirrhosis and related complications 17 -the relative benefit of SVR may indeed be substantially higher in patients with ongoing alcohol use-although the data to support this notion are lacking. The benefits of treating patients with ongoing drug abuse may extend beyond direct impact on patients' health to also limit the risk of transmission to others.
More importantly, these factors are potentially modifiable and can be targeted both at the PCP and specialty clinic levels to improve access to and receipt of DAA treatment.
Our study found substantial gaps in the pathway to anti-viral treatment. A substantial proportion of patients (37.4% of patients without follow-up, 16.4% of total) had relocated during the study follow-up; only 20.3% of these patients established liver care after moving to the other facility and even fewer received treatment.
Although reasons for lack of re-linkage with care may be (at least in part) patient-related, we believe that these patients represent yet
another important group that would need directed efforts to ensure delivery of HCV therapy. Our study also provides an insight into the healthcare disparity.
We found that although African Americans were as likely to be reseen in specialty clinics, they had significantly lower odds of receiv- Availability of these highly effective treatments, although necessary, is not sufficient to close the known chasm between efficacy and effectiveness of anti-viral in reducing HCV disease burden. Despite the system wide efforts to treat all patients, our data show many gaps, both at the patient and system-levels that were associated with lack of follow-up in HCV clinic and lack of treatment. Targeted efforts focusing on patients with modifiable mental and physical health co-morbidities may be the ways to make inroads into the problem of suboptimal treatment with the new highly effective DAAs.
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